Rhovac | Chosa Oncology

News published before 1 May 2017 in Swedish only.

2023

Feb 15, 2023

CHOSA team to participate at ASCO and present phase II data from the iCIP study

CHOSA has submitted an abstract presenting data on the first predictive biomarker for cisplatin and LiPlaCis in metastatic b...[Read more]

Feb 10, 2023

RhoVac AB changes name to CHOSA Oncology AB

Regulatory press release: The Swedish Companies Registration Office has registered the name change from RhoVac AB to CHOSA Oncology AB. The companys s...[Read more]

Jan 18, 2023

RhoVac AB (under name change to Chosa Oncology AB) has completed the acquisition of Chosa ApS and a new board and CEO have taken office

Regulatory press release: RhoVac AB (under name change to Chosa Oncology AB) (“RhoVac or the “Company) has today completed the acquisition of the Dani...[Read more]